Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 2Neoplasms 1Lymphoma 1

Interventions

Cyclophosphamide 69fludarabine phosphate 63Busulfan 45Peripheral Blood Stem Cell Transplantation 42Tacrolimus 40Mycophenolic Acid 37Filgrastim 35Antilymphocyte Serum 35fludarabine 31Cyclosporine 30Radiotherapy 29Melphalan 29Whole-Body Irradiation 27Methotrexate 24Etoposide 20Cord Blood Stem Cell Transplantation 18Biopsy 18Methylprednisolone 16Specimen Handling 15Rituximab 14Magnetic Resonance Spectroscopy 13Alemtuzumab 12Stem Cell Transplantation 11Granulocyte Colony-Stimulating Factor 11Cytarabine 11sargramostim 9Sirolimus 9Prednisone 9Dexamethasone 9plerixafor 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Drugs, Investigational × Plasma cell × Clear all
NCT04111107 2024-07-03

Precision Medicine for Patients With Identified Actionable Mutations

Wake Forest University Health Sciences

Phase 2 Terminated
45 enrolled 13 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡